ArticleThe Prostate2016
Trichomonas vaginalis infection and risk of advanced prostate cancer.
Article in The Prostate, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 24 citations in OpenAlex.
- Recent Advances in Biology, Host and Microbe Interactions of the Human Sexually Transmitted ParasiteInternational journal of molecular sciences · 2025Review
- No Association ofCancers · 2023Article
- Infinity war:Microbial cell (Graz, Austria) · 2023Review
- Multiple pathogens and prostate cancer.Infectious agents and cancer · 2022Review
- Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention.Cancers · 2022Review
- Trichomonas vaginalis serostatus and prostate cancer risk in Egypt: a case-control study.Parasitology research · 2021Article
- Molecular Examination ofEthiopian journal of health sciences · 2021Article
- Recent advances in the molecular biology of the protist parasiteFaculty reviews · 2021Review
- IL-6 produced by prostate epithelial cells stimulated with Trichomonas vaginalis promotes proliferation of prostate cancer cells by inducing M2 polarization of THP-1-derived macrophages.PLoS neglected tropical diseases · 2020Article
- Trichomonas vaginalis infection and prostate-specific antigen concentration: Insights into prostate involvement and prostate disease risk.The Prostate · 2019Article
- Increase Trichomonas vaginalis detection based on urine routine analysis through a machine learning approach.Scientific reports · 2019Article
- Association between Trichomonas vaginalis and prostate cancer mortality.International journal of cancer · 2019Article
- Comparison of Seropositivity to Trichomonas vaginalis between Men with Prostatic Tumor and Normal Men.The Korean journal of parasitology · 2019Article
- Trichomonas vaginalis infection and risk of prostate cancer: associations by disease aggressiveness and race/ethnicity in the PLCO Trial.Cancer causes & control : CCC · 2017Article
- Article
- Trichomoniasis immunity and the involvement of the purinergic signaling.Biomedical journal · 2016Review
- A prospective study of Trichomonas vaginalis and prostate cancer risk among African American men.BMC research notes · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundThe epidemiologic evidence for an association of Trichomonas vaginalis (Tv) with overall prostate cancer is mixed, but some studies suggest Tv may increase risk of more aggressive disease. The aim of this study was to assess whether Tv serostatus is associated with advanced or fatal prostate cancer.
methodsA total of 146 men with advanced (metastatic or fatal) prostate cancer and 181 age-matched controls were selected from two prior population-based, case-control studies. Tv serostatus was determined with the same laboratory methods used in previous epidemiologic studies. Odds ratios (OR) and 95% confidence intervals (CI) were calculated using multivariable logistic regression to compare Tv serostatus in prostate cancer cases and controls adjusted for potential confounders.
resultsThe seroprevalence of Tv in controls was 23%. Tv serostatus was not associated with an increased risk of metastatic or fatal prostate cancer (ORs < 1).
conclusionsOur study does not support an increased risk of advanced or fatal prostate cancer in men seropositive for Tv.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.